myeloMATCH Treatment Trials

MyeloMATCH is a group of clinical trials for people with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). These trials test new precision medicine treatments for patients with myeloid cancers, from diagnosis through multiple stages of their treatment journey.

myeloMATCH Links

Overview
Treatment Trials
For Patients (PDF)
For Physicians & Staff

Additional Resources

National Cancer Institute myeloMATCH page
myeloMATCH: The Next Revolution in the NCTN

myeloMATCH: Precision Medicine in Myeloid Cancer - AML | MDS

The myeloMATCH trial's screening protocol opened in May 2024.

New myeloMATCH treatment trials (sub-studies) will be opened regularly. The treatment trials below have just opened or will be opening shortly.

MM1OA-EA02, led by the ECOG-ACRIN Cancer Research Group
MM1YA-CTG01 (AL6), led by the Canadian Cancer Trials Group
MM1YA-S01, led by SWOG Cancer Research Network